Scynexis Inc

NASDAQ:SCYX   1:11:17 PM EDT
2.75
-0.07 (-2.48%)
Products, Regulatory

Scynexis Presents Positive Data From Its Pivotal Phase 3 Candle Study Of Oral Ibrexafungerp For Prevention Of Recurrent Vaginal Yeast Infections During 2022 Idsog Annual Meeting

Published: 08/04/2022 16:31 GMT
Scynexis Inc (SCYX) - Scynexis Presents Positive Data From Its Pivotal Phase 3 Candle Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 Idsog Annual Meeting.
Scynexis Inc- in Study, Ibrexafungerp Was Generally Safe and Well-tolerated.
Scynexis Inc- in Study, No Serious Drug-related Adverse Events, No Patients Treated With Ibrexafungerp Discontinued Therapy Due to Adverse Events.
Scynexis- Study Met Primary Endpoint, With 65.4% of Patients Who Got Monthly Single-day Ibrexafungerp Treatment Achieving Clinical Success With No Recurrence.